Tse, B. C., Said, B. I., Fan, Z. J., Hueniken, K., Patel, D., Gill, G., Liang, M., Razooqi, M., Brown, M. C., Sacher, A. G., Bradbury, P. A., Shepherd, F. A., Leighl, N. B., Xu, W., Howell, D., Liu, G., & O’Kane, G. (2020). Longitudinal health utilities, symptoms and toxicities in patients with ALK-rearranged lung cancer treated with tyrosine kinase inhibitors: a prospective real-world assessment. Curr Oncol, 27(6), e552-e559.
https://supportivecareresearch.ca/wp-content/themes/osmosis/images/empty/thumbnail.jpg 150 150 adm_supportive adm_supportive https://secure.gravatar.com/avatar/bc6ad3a0ea797d0735437331c50c7a4d4df9c1b461a1eb0e05ba0a0044a50729?s=96&d=mm&r=gTse, B. C., Said, B. I., Fan, Z. J., Hueniken, K., Patel, D., Gill, G., Liang, M., Razooqi, M., Brown, M. C., Sacher, A. G., Bradbury, P. A., Shepherd, F. A., Leighl, N. B., Xu, W., Howell, D., Liu, G., & O’Kane, G. (2020). Longitudinal health utilities, symptoms and toxicities in patients with ALK-rearranged lung cancer treated with tyrosine kinase inhibitors: a prospective real-world assessment. Curr Oncol, 27(6), e552-e559. https://doi.org/10.3747/co.27.6563
